COTA Life Sciences Vice President Viraj Narayanan in a recent interview with Outsourcing-Pharma discussed shifting opinions on real-world data and the COVID-19 pandemic’s influence on those attitudes.
“Most recently, because of COVID-19, we’ve experienced increased interest in RWD from sponsors,” he said during the interview. “As we slow down trials, we could speed things up with RWD — it’s digital and doesn’t require someone going to an office or a trial site.”
To read the full interview on Outsourcing-Pharma, click here.
